D
4D Molecular Therapeutics, Inc. FDMT
$8.40 -$0.15-1.75% NASDAQ
Recommendation
Prev Close
$8.39
Volume
451,671
Avg Vol (90D)
958,870
Market Cap
$391.83M
Dividend & Yield
--
52-Week Range
$2.24 - $11.20
P/E (TTM)
--
EPS (TTM)
-$3.52
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $30.40
10/6/2025 - Ticker Report
4D Molecular Therapeutics (FDMT, $8.55) RSI Indicator left the overbought zone on October 03, 2025
10/4/2025 - Tickeron - Stocks
4D Molecular Therapeutics Appoints New Financial Officer
10/2/2025 - TipRanks Financial Blog
4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $19,256.00 in Stock
10/2/2025 - Ticker Report
4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors
9/30/2025 - SeekingAlpha
4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors
9/30/2025 - Seeking Alpha - Long Ideas
Scott Bizily Sells 2,407 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock
9/29/2025 - MarketBeat
4D Molecular Therapeutics (FDMT, $8.44) RSI Indicator left the overbought zone on September 24, 2025
9/25/2025 - Tickeron - Stocks
4D Molecular Therapeutics (FDMT, $7.61) price may drop as it broke higher Bollinger Band on Sep 23, 2025
9/24/2025 - Tickeron - Stocks
4D Molecular Therapeutics (FDMT, $7.61) Moving Average Convergence Divergence (MACD) Histogram turned positive on September 23, 2025
9/24/2025 - Tickeron - Stocks
BMED's Holdings Imply 17% Gain Potential
9/22/2025 - ETF Channel
4D Molecular Therapeutics (FDMT, $6.6) entered Downtrend as Momentum indicator drops below 0 level on Sep 19, 2025
9/20/2025 - Tickeron - Stocks
H.C. Wainwright Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
9/19/2025 - TipRanks Financial Blog
4D Molecular Therapeutics, Inc. $FDMT Shares Bought by Acadian Asset Management LLC
9/18/2025 - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (D-)" Rating at Weiss Ratings
9/17/2025 - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Earns "Sell (D-)" Rating from Weiss Ratings
9/16/2025 - Ticker Report
4DMT Announces New Employment Inducement Grants
9/12/2025 - Globe Newswire
4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
9/9/2025 - Seeking Alpha: Transcripts
4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
9/9/2025 - SeekingAlpha
4D Molecular Therapeutics (FDMT, $6.97) entered Downtrend as Momentum indicator drops below 0 level on Sep 08, 2025
9/9/2025 - Tickeron - Stocks
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
9/8/2025 - Ticker Report
Nuveen LLC Invests $486,000 in 4D Molecular Therapeutics, Inc. $FDMT
9/7/2025 - MarketBeat
See How 4D Molecular Therapeutics Ranks Among Analysts' Top Picks With Strong Buyback Activity
9/5/2025 - The Online Investor
BVF Inc. IL Grows Position in 4D Molecular Therapeutics, Inc. $FDMT
9/5/2025 - MarketBeat
Jim Cramer on 4D Molecular Therapeutics: "This is a Pure Spec"
9/5/2025 - Insider Monkey
Income Statement
Total Revenue (TTM)
$33.00K
EBITDA (TTM)
-$215.82M
EBIT (TTM)
-$220.33M
Net Income (TTM)
-$196.14M
Balance Sheet
Total Assets (Q)
$473.64M
Total Debt (Q)
$23.08M
Total Liabilities (Q)
$52.75M
Book Value Per Share (Q)
$9.01
Cash Flow
Cash from Operations (TTM)
-$166.39M
Cash from Investing (TTM)
$52.46M
Cash from Financing (TTM)
$2.03M
Net Change in Cash (TTM)
-$111.90M
Filings
Filing Date
Monday, August 11, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
1.45
7-Day Total Return
18.31%
30-Day Total Return
15.70%
60-Day Total Return
98.11%
90-Day Total Return
118.18%
Year to Date Total Return
44.08%
1-Year Total Return
-22.44%
2-Year Total Return
-35.48%
3-Year Total Return
0.84%
5-Year Total Return
--
52-week Low
Apr 09, 2025 - $2.24
52-week High
Sep 27, 2024 - $11.20
Valuation
Market Cap
$391.83M - Small Cap
Enterprise Value
-$2.12M
Price/Sales (TTM)
16,780.00
Price/Book (Q)
0.93
Dividends and Shares
Shares Outstanding
55.93
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.4dmoleculartherapeutics.com
Phone Number
510 505 2680
Address
5858 Horton Street
EmeryVille, CA 94608
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform... more
NASDAQ 10/06/2025 4:00PM Eastern Quotes delayed